Quick Answer
Anebulo Pharmaceuticals, Inc. reported Net Income Loss of -$8.48 million for the year ending 2025.
- Anebulo Pharmaceuticals, Inc. showed a decrease of -3.5% in Net Income Loss from 2024 to 2025.
- This data is from Anebulo Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on September 29, 2025.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$174.6 thousand | Q3 2020: -$256.4 thousand | Q4 2020: -$328.6 thousand | Q1 2021: -$555.8 thousand | Q3 2021: -$1.55 million | Q4 2021: -$1.07 million | Q1 2022: -$1.88 million | Q3 2022: -$2.61 million | Q4 2022: -$3.83 million | Q1 2023: -$2.80 million | Q3 2023: -$2.48 million | Q4 2023: -$2.72 million | Q1 2024: -$1.65 million | Q3 2024: -$2.20 million | Q4 2024: -$2.46 million | Q1 2025: -$1.68 million | Q3 2025: -$2.16 million | Q4 2025: -$2.00 million.
- Over the full 5 years of available data (2021 to 2025), Anebulo Pharmaceuticals, Inc.'s Net Income Loss has grown by 72.0%.
- Historical annual values: Fiscal year 2025: -$8.48 million | Fiscal year 2024: -$8.20 million | Fiscal year 2023: -$11.73 million | Fiscal year 2022: -$6.83 million | Fiscal year 2021: -$30.25 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: